IOVANCE BIOTHERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $1.10 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-24
- IOVANCE BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2018-12-31 was -$1.50M, a 207.14% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2018-09-30 was -$800.00K, a 180.00% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2018-06-30 was -$1.70M, a 1800.00% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2018-03-31 was $6.30M, a 6200.00% increase year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $1.10M, a 10900.00% increase from fiscal 2023.
- IOVANCE BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $10.00K, a 75.00% decline from fiscal 2022.
- IOVANCE BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $40.00K, a 99.81% decline from fiscal 2021.
- IOVANCE BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $21.30M, a 0.47% decline from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2024-12-31 | $1.10M 10-K · filed 2026-02-24 | |||
| 2023-12-31 | $10.00K 10-K · filed 2026-02-24 | |||
| 2022-12-31 | $40.00K 10-K · filed 2025-02-27 | |||
| 2021-12-31 | $21.30M 10-K · filed 2024-02-28 | |||
| 2020-12-31 | $21.40M 10-K · filed 2023-02-28 | |||
| 2019-12-31 | $5.30M 10-K · filed 2022-02-24 | |||
| 2018-12-31 | -$1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$2.30M derived: sum of 2 quarters · filed 2021-02-25 | -$4.00M derived: sum of 3 quarters · filed 2021-02-25 | $2.30M 10-K · filed 2021-02-25 |
| 2018-09-30 | -$800.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | -$2.50M derived: sum of 2 quarters · filed 2018-11-06 | $3.80M 10-Q · filed 2018-11-06 | $5.20M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-06-30 | -$1.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $4.60M 10-Q · filed 2018-08-07 | $6.00M derived: sum of 3 quarters · filed 2020-02-25 | $7.00M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-03-31 | $6.30M 10-Q · filed 2018-05-10 | $7.70M derived: sum of 2 quarters · filed 2020-02-25 | $8.70M derived: sum of 3 quarters · filed 2020-02-25 | $8.80M derived: sum of 4 quarters · filed 2020-02-25 |
| 2017-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $2.40M derived: sum of 2 quarters · filed 2020-02-25 | $2.50M derived: sum of 3 quarters · filed 2020-02-25 | $2.60M 10-K · filed 2020-02-25 |
| 2017-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $1.10M derived: sum of 2 quarters · filed 2018-11-06 | $1.20M 10-Q · filed 2018-11-06 | |
| 2017-06-30 | $100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $200.00K 10-Q · filed 2018-08-07 | ||
| 2017-03-31 | $100.00K 10-Q · filed 2018-05-10 | |||
| 2016-12-31 | $200.00K 10-K · filed 2019-02-28 | |||
| 2015-12-31 | $0.00 10-K · filed 2018-03-12 | |||
| 2014-12-31 | $0.00 10-K · filed 2017-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |